Skip to main content
PlainMeds

What the label lists and what reports show

Latanoprost and netarsudil side effects

Latanoprost and netarsudil's FDA label: “The most common adverse reaction is conjunctival hyperemia (59%).” FAERS holds 939 reports naming it through July 30, 2026; the reaction reported most often, leaving out the conditions it is used for, product-use terms and outcomes, is ocular hyperaemia (144 reports).

  • No generic listed

Check it at the source: the latanoprost and netarsudil FDA label on DailyMed (effective August 27, 2026, Alcon Laboratories, Inc.); the FDA FAERS public dashboard.

What does the label list?

From the label: adverse reactions

The most common adverse reaction is conjunctival hyperemia (59%).

From the label: adverse reactions, continued

ADVERSE REACTIONS The most common adverse reaction is conjunctival hyperemia (59%). Other common adverse reactions were: instillation site pain (20%), corneal verticillata (15%), and conjunctival hemorrhage (11%). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Alcon Laboratories, Inc. at 1 800 757 9195, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The most common ocular adverse reaction observed in controlled clinical studies with ROCKLATAN was conjunctival hyperemia which was reported in 59% of patients. Five percent of patients discontinued therapy due to conjunctival hyperemia. Other common ocular adverse reactions reported were: instillation site pain (20%), corneal verticillata (15%), and conjunctival hemorrhage (11%). Eye pruritus, visual acuity reduced, increased lacrimation, instillation site discomfort, and blurred vision were reported in 5-8% of patients. …

Source: FDA drug label, Alcon Laboratories, Inc., effective August 27, 2026 (SPL set b1d71f41-be06-4a08-94d4-e352198f09c2), via openFDA; the full label on DailyMed

What do FAERS reports show?

939 reports list latanoprost and netarsudil among the medicines taken, each a report of something that happened, not proof the medicine caused it; 44 are coded as a death and 52 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Of the 20 reactions below, 7 are named by the same term (in US spelling) in the label's adverse reactions, warnings or patient leaflet; a reaction the label does not name may still be there under another word, and a report does not show that the medicine caused it.

Reports received each year

The 25 most reported reactions

  • Ocular Hyperaemia144
  • Eye Irritation109
  • Vision Blurred99
  • Conjunctival Hyperaemia (named in the label)94
  • Eye Pain (named in the label)79
  • Lacrimation Increased75
  • Product Dose Omission Issue (a use or a product term, not a reaction)71
  • Eye Pruritus (named in the label)62
  • Drug Ineffective (a use or a product term, not a reaction)41
  • Death (an outcome recorded in the report)38
  • Intraocular Pressure Increased34
  • Fatigue31
  • Headache30
  • Dry Eye (named in the label)29
  • Conjunctival Haemorrhage (named in the label)27
  • Visual Impairment27
  • Off Label Use (a use or a product term, not a reaction)26
  • Ocular Discomfort24
  • Diarrhoea20
  • Product Packaging Quantity Issue20
  • Dizziness19
  • Eye Swelling19
  • Visual Acuity Reduced (named in the label)19
  • Wrong Technique In Product Usage Process (a use or a product term, not a reaction)19
  • Photophobia (named in the label)18

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; reactions as MedDRA preferred terms

What next?

Latanoprost and netarsudil: the full record
label, generics, price, shortages, recalls
Side effects hub
the most reported medicines and reactions